FDA Approves LungFX™ Device to Increase Utilization of Donor Lungs for Transplantation

The U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for United Therapeutics Corporation's LungFX™ device. This device is designed for centralized ex vivo lung perfusion (EVLP), a procedure that allows donor lungs to be assessed outside the body before transplantation, aiming to reduce the high number of donor lungs currently unused.